Mainz Biomed (MYNZ) Common Equity (2020 - 2024)
Historic Common Equity for Mainz Biomed (MYNZ) over the last 6 years, with Q2 2025 value amounting to $2.5 million.
- Mainz Biomed's Common Equity rose 16094.54% to $2.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.5 million, marking a year-over-year increase of 16094.54%. This contributed to the annual value of $6.0 million for FY2024, which is 8609.18% up from last year.
- As of Q2 2025, Mainz Biomed's Common Equity stood at $2.5 million, which was up 16094.54% from $6.0 million recorded in Q4 2024.
- In the past 5 years, Mainz Biomed's Common Equity registered a high of $23.8 million during Q2 2022, and its lowest value of -$4.1 million during Q2 2024.
- Its 5-year average for Common Equity is $7.0 million, with a median of $5.6 million in 2023.
- Its Common Equity has fluctuated over the past 5 years, first soared by 33202.73% in 2021, then plummeted by 17993.8% in 2024.
- Mainz Biomed's Common Equity (Quarter) stood at $6.4 million in 2021, then skyrocketed by 121.6% to $14.1 million in 2022, then tumbled by 76.95% to $3.2 million in 2023, then skyrocketed by 86.09% to $6.0 million in 2024, then crashed by 58.28% to $2.5 million in 2025.
- Its Common Equity stands at $2.5 million for Q2 2025, versus $6.0 million for Q4 2024 and -$4.1 million for Q2 2024.